Porphyrias: A 2015 update

Clinics and Research in Hepatology and Gastroenterology

Volumn 39, Issue 4, 2015, Pages 412-425

  Karim, Zoubida ^a,b   Lyoumi, Said ^a,b,c   Nicolas, Gael ^a,b   Deybach, Jean Charles ^a,c,d,e   Gouya, Laurent ^a,c,d,e   Puy, Hervé ^a,c,d,e  

^a CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^b Laboratory of Excellence GR Ex   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HÔPITAL LOUIS MOURIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED CARBON; COLESTYRAMINE; COPROPORPHYRIN; HEME OXYGENASE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PORPHOBILINOGEN SYNTHASE; TRANSCRIPTION FACTOR GATA 1; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE; UROPORPHYRINOGEN III SYNTHASE;

ABDOMINAL PAIN; ACUTE INTERMITTENT PORPHYRIA; ACUTE LIVER FAILURE; ALLOGENIC BONE MARROW TRANSPLANTATION; BLISTER; BLOOD ANALYSIS; CANCER RISK; CLINICAL FEATURE; CONFUSION; CONGENITAL ERYTHROPOIETIC PORPHYRIA; CONSTIPATION; COPROPORPHYRIA; DISEASE SEVERITY; EARLY DIAGNOSIS; ERYTHROPOIETIC PROTOPORPHYRIA; FECES ANALYSIS; HEPATIC PORPHYRIA; HEPATOERYTHROPOIETIC PORPHYRIA; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; IRON OVERLOAD; LEAD POISONING; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LOSS OF FUNCTION MUTATION; METABOLITE; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; PORPHYRIA; PORPHYRIA CUTANEA TARDA; PORPHYRIA VARIEGATA; REVIEW; SEIZURE; SKIN FRAGILITY; TRYPTOPHAN BRAIN LEVEL; TYROSINEMIA; URINALYSIS; VOMITING; X LINKED ERYTHROPOIETIC PROTOPORPHYRIA; CLASSIFICATION; GENETICS; PORPHYRIAS; RISK FACTOR;

HUMANS; PORPHYRIAS; RISK FACTORS;

EID: 84940896763     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2015.05.009     Document Type: Review

References (65)

1. Puy H., Gouya L., Deybach J.C. Porphyrias. Lancet 2010, 375(9718):924-937.
2. Bissell D.M., Lai J.C., Meister R.K., Blanc P.D. Role of delta-aminolevulinic acid in the symptoms of acute porphyria. Am J Med 2015, 128(3):313-317.
3. Layer G., Reichelt J., Jahn D., Heinz D.W. Structure and function of enzymes in heme biosynthesis. Protein Sci 2010, 19(6):1137-1161.
4. Thunell S., Harper P., Brock A., Petersen N.E. Porphyrins, porphyrin metabolism and porphyrias. Scand J Clin Lab Invest 2000, 60:541-560.
5. Richardson D.R., Lane D.J., Becker E.M., Huang M.L., Whitnall M., Suryo RahmantoY, et al. Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. Proc Natl Acad Sci U S A 2010, 107(24):10775-10782.
6. Ponka P. Cell biology of heme. Am J Med Sci 1999, 318:241-256.
7. Besur S., Hou W., Schmeltzer P., Bonkovsky H.L. Clinically important features of porphyrin and heme metabolism and the porphyrias. Metabolites 2014, 4(4):977-1006.
8. Lyoumi S., Tamion F., Leplingard A., Beaumont C., Puy H., Lebreton J.P. Protective role of heme oxygenase and heme catabolites. Hematologie 2007, 13(4):251-265.
9. Balwani M., Desnick R.J. The porphyrias: advances in diagnosis and treatment. Blood 2012, 120(23):4496-4504.
10. Bonkovsky H.L., Maddukuri V.C., Yazici C., Anderson K.E., Bissell D.M., Bloomer J.R., et al. Acute porphyrias in the USA: features of 108 subjects from Porphyrias Consortium. Am J Med 2014, 127(12):1233-1241.
11. Lyoumi S., Abitbol M., Rainteau D., Karim Z., Bernex F., Oustric V., et al. Protoporphyrin retention in hepatocytes and Kupffer cells prevents sclerosing cholangitis in erythropoietic protoporphyria mouse model. Gastroenterology 2011, 141(4):1509-1519.
12. Elder G., Harper P., Badminton M., Sandberg S., Deybach J.C. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis 2013, 36(5):849-857.
13. Podvinec M., Handschin C., Looser R., Meyer U.A. Identification of the xenosensors regulating human 5-aminolevulinate synthase. Proc Natl Acad Sci U S A 2004, 101:9127-9132.
14. Handschin C., Lin J., Rhee J., Peyer A.K., Chin S., Wu P.H., et al. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell 2005, 122(4):505-515.
15. Delaby C., To-Figueras J., Deybach J.C., Casamitjana R., Puy H., Herrero C. Role of two nutritional hepatic markers (insulin-like growth factor 1 and transthyretin) in the clinical assessment and follow-up of acute intermittent porphyria patients. J Intern Med 2009, 266(3):277-285.
16. Danion F., Guillot M., Castelain V., Puy H., Deybach J.C., Schneider F. An uncommon option for surviving bariatric surgery: regaining weight!. Am J Med 2012, 125(11):1-2.
17. Laafi J., Homedan C., Jacques C., Gueguen N., Schmitt C., Puy H., et al. Pro-oxidant effect of ALA is implicated in mitochondrial dysfunction of HepG2 cells. Biochimie 2014, 106:157-166.
18. Degenhardt T., Väisänen S., Rakhshandehroo M., Kersten S., Carlberg C. Peroxisome proliferator-activated receptor alpha controls hepatic heme biosynthesis through ALAS1. J Mol Biol 2009, 388(2):225-238.
19. Homedan C., Laafi J., Schmitt C., Gueguen N., Lefebvre T., Karim Z., et al. Acute intermittent porphyria causes hepatic mitochondrial energetic failure in a mouse model. Int J Biochem Cell Biol 2014, 51:93-101.
20. Carichon M., Pallet N., Schmitt C., Lefebvre T., Gouya L., Talbi N., et al. Urinary metabolic fingerprint of acute intermittent porphyria analyzed by (1)H NMR spectroscopy. Anal Chem 2014, 86(4):2166-2174.
21. Pozo O.J., Marcos J., Fabregat A., Ventura R., Casals G., Aguilera P., et al. Adrenal hormonal imbalance in acute intermittent porphyria patients: results of a case control study. Orphanet J Rare Dis 2014, 9:54-65.
22. Soonawalla Z.F.O.T., Badminton M.N., Elder G.H., Rhodes J.M., Bramhall S.R., Elias E. Liver transplantation as a cure for acute intermittent porphyria. Lancet 2004, 363(9410):705-706.
23. Wahlin S., Harper P., Sardh E., Andersson C., Andersson D.E., Ericzon B.G. Combined liver and kidney transplantation in acute intermittent porphyria. Transpl Int 2010, 23(6):e18-e21.
24. Singal A.K., Parker C., Bowden C., Thapar M., Liu L., McGuire B.M. Liver transplantation in the management of porphyria. Hepatology 2014, 60(3):1082-1089.
25. Yin Z., Wahlin S., Ellis E.C., Harper P., Ericzon B.G., Nowak G. Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria. Cell Transplant 2014, 23(9):1153-1162.
26. Yasuda M., Gan L., Chen B., Kadirvel S., Yu C., Phillips J.D., et al. RNAi-mediated silencing of hepatic ALAS1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice. Proc Natl Acad Sci U S A 2014, 111(21):7777-7782.
27. Pallet N., Mami L., Schmitt C., Karim Z., François A., Rabant M., et al. High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria. Kidney Intern 2015, [Epub ahead of print]. 10.1038/ki.2015.97.
28. Sardh E., Wahlin S., Björnstedt M., Harper P., Andersson D.E. High risk of primary liver cancer in a cohort of 179 patients with acute hepatic porphyria. J Inherit Metab Dis 2013, 36(6):1063-1071.
29. Deybach J.C., Puy H. Hepatocellular carcinoma without cirrhosis: think acute hepatic porphyrias and vice versa. J Intern Med 2011, 269(5):521-524.
30. Innala E., Andersson C. Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden. J Intern Med 2011, 269(5):538-545.
31. Schneider-Yin X., van Tuyll van Serooskerken A., Siegesmund M., Went P., Barman-Aksözen J., et al. Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias. J Hepatol 2015, 62(3):734-738. [Epub 2014 Nov 28]. 10.1016/j.jhep.2014.11.029.
32. Schulenburg-Brand D., Katugampola R., Anstey A.V., Badminton M.N. The cutaneous porphyrias. Dermatol Clin 2014, 32(3):369-384.
33. Aarsand A.K., Villanger J.H., Støle E., Deybach J.C., Marsden J., To-Figueras J., et al. European specialist porphyria laboratories: diagnostic strategies, analytical quality, clinical interpretation, and reporting as assessed by an external quality assurance program. Clin Chem 2011, 57(11):1514-1523. [Erratum in: Clin Chem 2012;58(2):476].
34. Elder G.H. Porphyria cutanea tarda and related disorders. The porphyrin handbook: medical aspects of porphyria 2003, 67-92. Academic Press, San Diego. 14. K.M. Kadish, K.M. Smith, R. Guilard (Eds.).
35. Ryan Caballes F., Sendi H., Bonkovsky H.L. Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver Int 2012, 32(6):880-893.
36. Fleming R.E., Ponka P. Iron overload in human disease. N Engl J Med 2012, 366(4):348-359.
37. Ajioka R.S., Phillips J.D., Weiss R.B., Dunn D.M., Smit M.W., Proll S.C., et al. Down-regulation of hepcidin in porphyria cutanea tarda. Blood 2008, 112(12):4723-4728.
38. Darwich E., To-Figueras J., Molina-López R.A., Deulofeu R., Olbina G., Westerman M., et al. Increased serum hepcidin levels in patients with porphyria cutanea tarda. J Eur Acad Dermatol Venereol 2013, 27(1):e68-e74.
39. Phillips J.D., Bergonia H.A., Reilly C.A., Franklin M.R., Kushner J.P. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci U S A 2007, 104(12):5079-5084.
40. Danton M., Lim C.K. Porphomethene inhibitor of uroporphyrinogen decarboxylase: analysis by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Biomed Chromatogr 2007, 21(7):661-663.
41. Tchernitchko D., Robréau A.M., Lefebvre T., Lamoril J., Deybach J.C., Puy H. Comprehensive cytochrome P450 CYP1A2 gene analysis in French caucasian patients with familial and sporadic porphyria cutanea tarda. Br J Dermatol 2012, 166(2):425-429.
42. Aguilera P., Laguno M., To-Figueras J. Treatment of chronic hepatitis with boceprevir leads to remission of porphyria cutanea tarda. Br J Dermatol 2014, 171(6):1595-1596.
43. Singal A.K., Kormos-Hallberg C., Lee C., Sadagoparamanujam V.M., Grady J.J., Freeman D.H., et al. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol 2012, 10(12):1402-1409.
44. Murphy G.M. Diagnosis and management of the erythropoietic porphyrias. Dermatol Ther 2003, 16:57-64.
45. Holme S.A., Worwood M., Anstey A.V., Elder G.H., Badminton M.N. Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. Blood 2007, 110:4108-4110.
46. Lyoumi S., Abitbol M., Andrieu V., Henin D., Robert E., Schmitt C., et al. Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice. Blood 2007, 109:811-818.
47. Holme S.A., Whatley S.D., Roberts A.G., Anstey A.V., Elder G.H., Ead R.D., et al. Seasonal palmar keratoderma in erythropoietic protoporphyria indicates autosomal recessive inheritance. J Invest Dermatol 2009, 129(3):599-605.
48. Park P.J., Hwang S., Choi Y.I., Yu Y.D., Park G.C., Jung S.W., et al. Liver transplantation for acute-on-chronic liver failure from erythropoietic protoporphyria. Clin Mol Hepatol 2012, 18(4):411-415.
49. Schmitt C., Ducamp S., Gouya L., Deybach J.C., Puy H. Inheritance in erythropoietic protoporphyria. Pathol Biol (Paris) 2010, 58(5):372-380.
50. Gouya L., Martin-Schmitt C., Robreau A.M., Austerlitz F., Da Silva V., Brun P., et al. Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. Am J Hum Genet 2006, 78:2-14.
51. Oustric V., Manceau H., Ducamp S., Soaid R., Karim Z., Schmitt C., et al. Antisense oligonucleotide-based therapy in human erythropoietic protoporphyria. Am J Hum Genet 2014, 94(4):611-617.
52. Lecha M., Puy H., Deybach J.C. Erythropoietic protoporphyria. Orphanet J Rare Dis 2009, 4:19.
53. Biolcati G., Marchesini E., Sorge F., Barbieri L., Schneider-Yin X., Minder E.I. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol 2015, 172(6):1601-1612. [Epub 2015 Apr 30]. 10.1111/bjd.13598.
54. Minder E.I., Schneider-Yin X. Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert Rev Clin Pharmacol 2015, 8(1):43-53.
55. Abitbol M., Puy H., Sabaté J.M., Guénet J.L., Deybach J.C., Montagutelli X. Ursodesoxycholic acid and heme-arginate are unable to improve hematopoiesis and liver injury in an erythropoietic protoporphyria mouse model. Physiol Res 2006, 55(Suppl. 2):S93-S101.
56. Whatley S.D., Gouya L., Grandchamp B., Beaumont C., Badminton M.N., Elder G.H., et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 2008, 83:408-414.
57. Balwani M., Doheny D., Bishop D.F., Nazarenko I., Yasuda M., Dailey H.A., et al. Loss-of-function ferrochelatase and gain-of-function erythroid-specific 5-aminolevulinate synthase mutations causing erythropoietic protoporphyria and X-linked protoporphyria in North American patients reveal novel mutations and a high prevalence of X-linked protoporphyria. Mol Med 2013, 19:26-35.
58. Livideanu C.B., Ducamp S., Lamant L., Gouya L., Rauzy O.B., Deybach J.C., et al. Late-onset x-linked dominant protoporphyria: an etiology of photosensitivity in the elderly. J Invest Dermatol 2013, 133(6):1688-1690.
59. Ducamp S., Schneider-Yin X., de Rooij F., Clayton J., Fratz E.J., Rudd A., et al. Molecular and functional analysis of the c-terminal region of human erythroid specific δ-aminolevulinic synthase associated with x-linked dominant protoporphyria (XLDPP). Hum Mol Genet 2013, 22(7):1280-1288.
60. Ducamp S., Kannengiesser C., Touati M., Garçon L., Guerci-Bresler A., Guichard J.F., et al. Sideroblastic anemia: molecular analysis of the ALAS2 gene in a series of 29 probands and functional studies of 10 missense mutations. Hum Mutat 2011, 32(6):590-597.
61. Bishop D.F., Tchaikovskii V., Nazarenko I., Desnick R.J. Molecular expression and characterization of erythroid-specific 5-aminolevulinate synthase gain-of-function mutations causing X-linked protoporphyria. Mol Med 2013, 19:18-25.
62. Katugampola R.P., Anstey A.V., Finlay A.Y., Whatley S., Woolf J., Mason N., et al. Amanagement algorithm for congenital erythropoietic porphyria derived from a study of 29 cases. Br J Dermatol 2012, 167(4):888-900.
63. Phillips J.D., Steensma D.P., Pulsipher M.A., Spangrude G.J., Kushner J.P. Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. Blood 2007, 109(6):2618-2621.
64. To-Figueras J., Ducamp S., Clayton J., Badenas C., Delaby C., Ged C., et al. ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria. Blood 2011, 118(6):1443-1451.
65. Blouin J.M., Duchartre Y., Costet P., Lalanne M., Ged C., Lain A., et al. Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria. Proc Natl Acad Sci U S A 2013, 110(45):18238-18243.